GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gossamer Bio Inc (FRA:4GB) » Definitions » Institutional Ownership

Gossamer Bio (FRA:4GB) Institutional Ownership : 17.80% (As of Jun. 19, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Gossamer Bio Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Gossamer Bio's institutional ownership is 17.80%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Gossamer Bio's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Gossamer Bio's Float Percentage Of Total Shares Outstanding is 97.08%.


Gossamer Bio Institutional Ownership Historical Data

The historical data trend for Gossamer Bio's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gossamer Bio Institutional Ownership Chart

Gossamer Bio Historical Data

The historical data trend for Gossamer Bio can be seen below:

2023-08-31 2023-09-30 2023-10-31 2023-11-30 2023-12-31 2024-01-31 2024-02-29 2024-03-31 2024-04-30 2024-05-31
Institutional Ownership 6.16 16.10 19.53 21.20 20.61 20.60 19.70 17.91 17.80 17.80

Gossamer Bio Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Gossamer Bio (FRA:4GB) Business Description

Traded in Other Exchanges
Address
3013 Science Park Road, Suite 200, San Diego, CA, USA, 92121
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.

Gossamer Bio (FRA:4GB) Headlines

No Headlines